← Eichor
Study identifier: NCT05328024 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma

Condition: Head and Neck Cancer  ·  Sponsor: Centre Paul Strauss

PhaseN/A
Planned participants60
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This project aims to organise the sampling of blood and tumor at key points of the standard of care of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (HNSCC). This will allow to identify new potential predictive biomarkers of efficacy of immunotherapy and to investigate the evolution of the tumoral microenvironment after successive systemic treatments.

This description comes directly from the study's public registry record.

Talk to the study team

Valérie SARTORI  ·  03 68 33 95 23  ·  promotion-rc@icans.eu

Manon VOEGELIN  ·  03 68 33 95 23  ·  promotion-rc@icans.eu

Always discuss trial participation with your own doctor first.

Locations (1)

Institut de cancérologie Strasbourg EuropeStrasbourg, France, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05328024